US Pharma MarketingThe post FDA clears Quoin Pharmaceuticals’ QRX003 IND for Phase II PSS trial appeared first on Clinical Trials Arena.
FDA clears Quoin Pharmaceuticals’ QRX003 IND for Phase II PSS trial
Quoin Pharmaceuticals has received FDA clearance for its IND application for QRX003, enabling it to initiate a Phase II clinical trial for a treatment for Peeling Skin Syndrome (PSS). The planned study will enrol six to eight paediatric and adult patients with PSS in the US and Europe. Peeling Skin Syndrome is a rare genetic disorder affecting the epidermis. Credit: Irishasel / Shutterstock.com. Quoin Pharmaceuticals has received clearance from the US Food and Drug Administration (FDA) for its investigational new drug (IND) application for QRX003, enabling it to initiate a Phase II clinical trial for a treatment for Peeling Skin…
Quoin Pharmaceuticals has received FDA clearance for its IND application for QRX003, enabling it to initiate a Phase II clinical trial for a treatment for Peeling Skin Syndrome (PSS).
Source: Clinical Trials Arena